【摘要】 目的:分析索他洛尔与胺碘酮治疗心房颤动的心房颤动复律及安全性。方法:选取某院2016年1月~2017年2月收治的100例心房颤动患者资料,将行胺碘酮医治的50例患者设为研究组,行索他洛尔医治的50例患者设为对照组,比对两组心功能指标、疗效指标及副反应状况。结果:研究组Pmax、Pd等指标水平(112.01±11.28)ms、(45.46±6.10)ms比对照组优,复律时间、房颤发作次数等(4.20±1.42)h、(5.80±0.92)次比对照组优,副反应总发生率(12.00%)比对照组(28.00%)低,差异显著具统计学意义(P<0.05)。结论:心房颤动患者行胺碘酮医治可缩短心房颤动复律的时间,改善心功能,降低并发症总发生率。更多还原

【Abstract】 Objective:To analyze the cardioversion and safety of sotalol and amiodarone in the treatment of atrial fibrillation.Methods:The clinical data of 100 patients with atrial fibrillation treated in a hospital from January 2016 to February 2017 were selected.The 50 cases treated with amiodarone were taken as the study group,whereas the other 50 patients given sotalol for treatment were set as the control group.The cardiac function index,curative effect and adverse reactions were compared between the two groups.Results:The levels of Pmax and Pd in the study group were respectively(112.01±11.28)ms and(45.46±6.10)ms,both better than the control group;time of cardioversion and attack frequency of atrial fibrillation in the study group were respectively(4.20±1.42)h and(5.80±0.92)times,better than the control group;The total incidence of adverse reactions in the study group(12.00%)was lower than that in the control group(28.00%),and the differences between the two groups were statistically significant(P<0.05).Conclusion:For patients with atrial fibrillation,amiodarone can shorten the time of cardioversion,improve their cardiac function,and reduce the total incidence of complications.更多还原